Canna~Fangled Abstracts

The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus.

By November 4, 2019 November 9th, 2019 No Comments
2019 Nov 4;19(11):117. doi: 10.1007/s11892-019-1248-9.
Veilleux A1,2,3, Di Marzo V1,2,3,4,5, Silvestri C6,7,8.

Abstract

PURPOSE OF REVIEW:

The endocannabinoid (eCB) system, i.e. the receptors that respond to the psychoactive component of cannabis, their endogenous ligands and the ligand metabolic enzymes, is part of a larger family of lipid signals termed the endocannabinoidome (eCBome). We summarize recent discoveries of the roles that the eCBome plays within peripheral tissues in diabetes, and how it is being targeted, in an effort to develop novel therapeutics for the treatment of this increasingly prevalent disease.

RECENT FINDINGS:

As with the eCB system, many eCBome members regulate several physiological processes, including energy intake and storage, glucose and lipid metabolism and pancreatic health, which contribute to the development of type 2 diabetes (T2D). Preclinical studies increasingly support the notion that targeting the eCBome may beneficially affect T2D. The eCBome is implicated in T2D at several levels and in a variety of tissues, making this complex lipid signaling system a potential source of many potential therapeutics for the treatments for T2D.

KEYWORDS: Bioactive lipids, Endocannabinoidome, Glucose, Insulin, Peripheral tissues

PMID: 31686231
DOI: 10.1007/s11892-019-1248-9

Publication type

Publication type

Leave a Reply

en English